3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Neoplasm Metastasis
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Stomach Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Fluorouracil
17
Cisplatin
17
pembrolizumab
12
Radiotherapy
11
Oxaliplatin
10
Irinotecan
9
Paclitaxel
6
Leucovorin
6
Docetaxel
6
Carboplatin
6
Capecitabine
6
Neoadjuvant Therapy
5
Trastuzumab
4
Panitumumab
4
Gefitinib
4
Esophagectomy
4
Cyclophosphamide
4
Cetuximab
4
Surgical Procedures, Operative
3
Celecoxib
3
tegafur-gimeracil-oteracil
2
spartalizumab
2
sodium glycididazole
2
niraparib
2
fludarabine
2
S 1 (combination)
2
Plicamycin
2
Pemetrexed
2
Lapatinib
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Esophageal Neoplasms
×
Folfox protocol
×
Clear all
NCT03528876
2020-11-02
LOGIC
University of Saskatchewan
Phase 2
Terminated
36 enrolled